Literature DB >> 8800308

Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.

H Zachariae1, L Halkier-Sørensen, P Bjerring, L Heickendorff.   

Abstract

Twelve patients with systemic sclerosis were treated with intravenous infusions of the prostacyclin-stable analogue iloprost 0.5-2.0 ng/kg/min for 6 h from 8 to 13 days. Imminent gangrene was stopped in 2 patients and followed by healing. In 4 of 6 patients iloprost led to complete healing of ischaemic ulcers and in the remaining 2 patients to partial healing. One patient with severe Raynaud's phenomenon discontinued the study after 3 days due to severe headache. The 2 remaining patients with Raynaud's phenomenon as an indication improved, while no improvement was recorded in a patient with vasculitis of the lower leg. Side-effects such as headache, nausea and flushing were the reason that only 5 patients reached the maximum infusion rate. No statistical differences were recorded in digital bloodflow before and after the study or in plasma endothelin in the 9 patients investigated. Three of the 6 patients with healing ulcers, however, showed a pronounced decrease in plasma endothelin. Iloprost appears useful as a treatment of imminent gangrene and ischaemic ulcers in systemic sclerosis. This reparatory capacity could also be of a more general importance in therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800308     DOI: 10.2340/0001555576236238

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

Review 1.  Practical approach to the therapy of systemic sclerosis.

Authors:  L Czirják
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

Review 2.  Points to consider for skin ulcers in systemic sclerosis.

Authors:  Felice Galluccio; Yannick Allanore; Lázló Czirjak; Daniel E Furst; Dinesh Khanna; Marco Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.